LXRX Lexicon Pharmaceuticals, Inc.

An analyst at a prominent research firm initiated coverage of the

Investing.com -- Shares of Lexicon Pharmaceuticals Inc (NASDAQ:LXRX) rallied over 13% in Monday morning trading following a bullish initiation of coverage from Wall Street research firm Cantor Fitzgerald. The broker set an Overweight rating and an $8.00 price target on the biopharmaceutical company, reflecting substantial upside potential driven by the company’s ongoing late-stage cardiovascular research program.

Lexicon Pharmaceuticals (NASDAQ:LXRX) said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first quarter of 2027. Speaking at the H.C. Wainwright 28th Annual Global Investment Conference, Chief Executiv

Lexicon announced the payment after Novo Nordisk hit a key patient-dosing target in the early-stage trial of LX9851.

Novo Nordisk (CPSE:NOVO B) and Lexicon Pharmaceuticals reached a key milestone in the development of first in class oral obesity drug LX9851. Lexicon received a milestone payment from Novo Nordisk tied to clinical progress for LX9851 in obesity and metabolic disorders. The advancement of LX9851 adds a new mechanism of action to Novo Nordisk's obesity pipeline alongside its existing treatments. The update underscores ongoing efforts to address obesity as a major global health challenge with...

SONATA-HCM Phase III enrollment topped 500 patients; data due Q1 2027.

In early August 2026, Lexicon Pharmaceuticals reported second-quarter results showing revenue of US$692,000 versus US$28.87 million a year earlier, alongside a shift from net income of US$3.25 million to a net loss of US$31.78 million and wider per-share losses. On the same day, the company filed two shelf registrations totaling about US$44.73 million in common stock capacity, highlighting both the strain on its current financial position and its intention to preserve flexibility for future...

Lexicon Pharmaceuticals Inc (LXRX) advances its pipeline with strong cash position despite a challenging quarter marked by a net loss and reduced revenues.

Lexicon Pharmaceuticals (NASDAQ:LXRX) reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III SONATA-HCM trial and outlined plans to resubmit a new drug application for ZYNQUISTA in type 1 diabet

Lexicon (LXRX) delivered earnings and revenue surprises of 0.00% and -88.73%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Recursion Pharmaceuticals (RXRX) delivered earnings and revenue surprises of -8.70% and -46.77%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Lexicon Pharmaceuticals (LXRX) is back in focus after reporting completion of patient randomization in its global Phase 3 SONATA HCM trial of sotagliflozin in hypertrophic cardiomyopathy, with enrollment beyond the original target. See our latest analysis for Lexicon Pharmaceuticals. Against this backdrop, Lexicon Pharmaceuticals’ share price sits at US$2.32, with a 90 day share price return of 44.10% and year to date share price return of 103.51%. The 1 year total shareholder return of...